Hansoh Pharma's Shengluolai® Presents Two New Studies at ERA 2026 Highlighting Combination Therapy and Optimized Dosing

(Source: Progress in Pharmaceutical Sciences)

Hansoh Pharma's Saint-Roche®Two Research Findings Unveiled, Focusing on Combination Therapy and Optimized Dosing PPS 

The 2026 European Renal Association Congress (ERA 2026) was held in Glasgow, UK, from June 3 to 6. At this premier global academic event in the field of nephrology, Hansoh Pharma’s independently developed long-acting erythropoietin (EPO) mimetic peptide, Shengluolai®(Pemiglustat Injection) Two research findings were presented as posters. These studies focused respectively on the synergistic potential of combination therapy strategies and the clinical feasibility of optimized dosing regimens, providing new insights for the management of renal anemia.[1,2]。

Abstract No: 2187

Study Title: Synergistic Erythropoietic Effects and Safety of Pegmolesatide Combined with Roxadustat in a Rat Model of Chronic Kidney Disease‑Associated Anemia

Research Highlights: Pegmolesatide Combined with HIF-PHI Shows Synergistic Efficacy and Good Safety Profile

This study validated the synergistic effect of pemvidutide combined with hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) by establishing a rat model of chronic kidney disease (CKD)-associated anemia and conducting a systematic evaluation.

Study Findings: After 5 weeks of treatment, pegmolesatide monotherapy increased hemoglobin (Hb) by 31.20%, whereas low-dose HIF-PHI monotherapy increased it by only 9.16%. In contrast, the combination therapy resulted in a substantial Hb increase of 44.98%, demonstrating a clear synergistic effect. When combined with medium-dose HIF-PHI, the Hb increase reached 54.10%, surpassing the 48.14% observed with monotherapy.

Notably, the decline in hemoglobin (Hb) levels after discontinuation was more gradual in the combination therapy group, helping to mitigate the risk of Hb fluctuations commonly observed in clinical practice. In terms of safety, pemaquistat did not interfere with HIF-PHI-induced endogenous erythropoietin (EPO) production, and the combination therapy had no significant impact on renal function or liver enzymes.

Studies suggest that the combination of pemvidutide and HIF-PHI may emerge as a new therapeutic option for patients with refractory renal anemia who exhibit a poor response to conventional erythropoiesis-stimulating agents (ESAs) or require high-dose administration.

Abstract No: 2610

Research Title: Optimized Dosing of Pegmolesatide in Renal Anemia: Comparable Early Efficacy

Research Highlights: The optimized dosing regimen of pemivacimab demonstrates efficacy comparable to the standard regimen and simplifies treatment.

This study is an interim analysis of an ongoing randomized controlled trial, aimed at comparing the early efficacy of the optimized dosing regimen of pemoquitide with the standard dosing regimen.

Ninety-four patients were randomly assigned to either the standard dosing group (initial recommended dose and dose adjustment regimen per the product label) or the optimized dosing group (fixed initial dose and a dose adjustment regimen based on 0.4 mg increments). Baseline characteristics and mean hemoglobin (Hb) levels were comparable between the two groups (88.6 g/L in the standard group vs. 90.0 g/L in the optimized group). After three months of treatment, there were no significant differences between the groups in terms of Hb increase, target attainment rate, or time to target attainment: the target attainment rates were 30.2% and 30.0%, respectively (P=0.98), median time to target achievement was 59 days vs 42 days (P=0.80). Secondary endpoints, including red blood cell count and hematocrit, also showed no intergroup differences (allP＞0.05）。

Studies have shown that the optimized dosing regimen of pegmolesatide demonstrates early efficacy comparable to the standard dosing regimen in improving anemia-related indicators, thereby supporting the feasibility of the optimized regimen as a simplified treatment strategy.

From Frontier Exploration of Combination Therapy Strategies to Clinical Validation of Optimized Dosing Regimens, Shengluolai®Two research studies presented at ERA 2026 have once again affirmed the unique value of this long-acting small-molecule peptide drug. On one hand, it offers a more effective new treatment option for patients with refractory renal anemia by providing complementary mechanisms and synergistic effects with novel oral HIF-PHI drugs. On the other hand, the optimized dosing regimen simplifies the treatment process while maintaining efficacy, helping to reduce the healthcare burden on patients and improve long-term treatment adherence and quality of life.

These studies not only expand the clinical management paradigm for renal anemia but also reflect a patient-centered innovative approach, contributing to improved long-term outcomes in patients with chronic kidney disease (CKD).

References:

1.Xiaoying MA,et al. Synergistic Erythropoietic Effects and Safety of Pegmolesatide Combined with Roxadustat in a Rat Model of Chronic Kidney Disease‑Associated Anemia.ERA 2026. Abstract No: 2187

2.Jinbo Yu,et al. Optimized Dosing of Pegmolesatide in Renal Anemia: Comparable Early Efficacy.ERA 2026. Abstract No: 2610

Layout Design: Tong Wenjing

Article Review: Song Shuhao, Tong Wenjing, Luo Qi

【Disclaimer] The above content is sourced from the internet and does not represent the position or views of this platform. If there is any infringement of the author's copyright, please contact us promptly (Tel: 025-83271227, or leave a message directly on the WeChat platform), and we will correct or delete it in a timely manner.